UroGen Pharma (NASDAQ:URGN) Given New $53.50 Price Target at LADENBURG THALM/SH SH

UroGen Pharma (NASDAQ:URGNFree Report) had its price objective increased by LADENBURG THALM/SH SH from $48.00 to $53.50 in a research note issued to investors on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright increased their price objective on shares of UroGen Pharma from $54.00 to $60.00 and gave the stock a buy rating in a research note on Friday. Oppenheimer raised their price target on UroGen Pharma from $32.00 to $40.00 and gave the stock an outperform rating in a report on Friday.

Get Our Latest Research Report on UroGen Pharma

UroGen Pharma Stock Performance

NASDAQ:URGN opened at $18.28 on Friday. The stock has a 50-day simple moving average of $13.86 and a 200 day simple moving average of $15.08. UroGen Pharma has a one year low of $8.69 and a one year high of $24.13. The company has a market capitalization of $428.67 million, a price-to-earnings ratio of -5.38 and a beta of 1.08.

UroGen Pharma (NASDAQ:URGNGet Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The firm had revenue of $18.78 million during the quarter, compared to analyst estimates of $20.73 million. On average, equities research analysts forecast that UroGen Pharma will post -3.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 5,153 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $13.08, for a total transaction of $67,401.24. Following the completion of the transaction, the insider now directly owns 144,284 shares in the company, valued at $1,887,234.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 11.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC lifted its holdings in UroGen Pharma by 31.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 4,955 shares of the company’s stock worth $74,000 after purchasing an additional 1,191 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of UroGen Pharma by 65.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,903 shares of the company’s stock worth $89,000 after buying an additional 2,328 shares in the last quarter. Jump Financial LLC lifted its stake in shares of UroGen Pharma by 12.6% in the 4th quarter. Jump Financial LLC now owns 33,320 shares of the company’s stock worth $500,000 after acquiring an additional 3,720 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of UroGen Pharma by 40.4% in the fourth quarter. BNP Paribas Financial Markets now owns 22,996 shares of the company’s stock valued at $345,000 after acquiring an additional 6,617 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of UroGen Pharma by 38.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,766 shares of the company’s stock valued at $417,000 after acquiring an additional 8,260 shares during the period. Institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

(Get Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Featured Stories

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.